Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib

被引：0
|
作者：
Hua Cheng
She-Juan An
Song Dong
Yi-Fang Zhang
Xu-Chao Zhang
Zhi-Hong Chen
Yi-Long Jian-Su
机构：
[1] Guangdong Lung Cancer Institute; Medical Research Center of Guangdong General Hospital & Guangdong Academy of Medical Sciences,
[2] Thoracic oncology,undefined
[3] the fifth affiliated hospital of Sun Yat-Sen university,undefined
来源：
Journal of Hematology & Oncology | / 4卷
关键词：
Paclitaxel; Gefitinib; Erlotinib; H1650 Cell; Combination Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
    Cheng, Hua
    An, She-Juan
    Dong, Song
    Zhang, Yi-Fang
    Zhang, Xu-Chao
    Chen, Zhi-Hong
    Jian-Su
    Wu, Yi-Long
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
  • [2] Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
    Naito, Yoichi
    Goto, Koichi
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1027 - 1040
  • [3] Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
    Kim, Youjin
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Sun, Jong-Mu
    CANCER RESEARCH AND TREATMENT, 2019, 51 (02): : 502 - 509
  • [4] Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Padole, Atul
    Chen, Tianqi
    Peterson, P. Gabriel
    Piotrowska, Zofia
    Sequist, Lecia, V
    CANCERS, 2019, 11 (09)
  • [5] Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines
    Piperdi, Bilal
    Ling, Yi-He
    Perez-Soler, Roman
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 715 - 721
  • [6] Prognostic value of EGFR genotype in EGFR-mutant non-small cell lung cancer
    Syrigos, Konstantinos
    Kotteas, Ilias
    Paraskeva, Maria
    Gkiozos, Ioannis
    Boura, Paraskevi
    Tsagouli, Sofia
    Grapsa, Dimitra
    Charpidou, Andriani
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [7] Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines
    Naga, Shinjiro
    Takenaka, Kazumasa
    Sonobe, Makoto
    Wada, Hiromi
    Tanaka, Fumihiro
    CHEMOTHERAPY, 2008, 54 (03) : 166 - 175
  • [8] Osimertinib in EGFR-mutant non-small cell lung carcinoma
    Lorenz, Judith
    PNEUMOLOGIE, 2023, 77 (11): : 847 - 847
  • [9] Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms
    Jiang, Yanwen
    Yuan, Qing
    Fang, Qiuhong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (07) : 1087 - 1095
  • [10] Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms
    Yanwen Jiang
    Qing Yuan
    Qiuhong Fang
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1087 - 1095
12345